Welcome to our dedicated page for RADIOPHARM THRNSTCS S/ADR news (Ticker: RADTY), a resource for investors and traders seeking the latest updates and insights on RADIOPHARM THRNSTCS S/ADR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RADIOPHARM THRNSTCS S/ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RADIOPHARM THRNSTCS S/ADR's position in the market.
Deutsche Bank has been appointed as the depositary bank for the American Depositary Receipt (ADR) program of Radiopharm Theranostics (OTC: RADTY). Radiopharm is a clinical stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has been listed on ASX (RAD) since November 2021 and has a pipeline of distinct platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer treatment.
The ADR program details include:
- Country: Australia
- Custodian Bank: BNP Paribas S.A.
- Effective Date: September 18, 2024
- Level I ADR
- Symbol: RADTY
- Exchange: OTC
- Current Ratio: 1 ADS : 200 ordinary shares
